January 30, 2015 4:47 AM ET


Company Overview of Bicycle Therapeutics Limited

Company Overview

Bicycle Therapeutics Limited, a biotherapeutics company, focuses on developing highly constrained bicyclic peptides (bicycles) as novel class of therapeutics. The company is involved in developing a pipeline of bicycle molecules by using its proprietary bicyclic peptide technology that provide antibody-like affinity and selectivity in a much smaller chemically synthesized molecule. It applies its technology to various drug discovery projects, including oncology, ophthalmology, and other therapeutic areas through collaborative discovery partnerships with pharmaceutical companies. Bicycle Therapeutics Limited was founded in 2009 and is based in Cambridge, United Kingdom.

Meditrina Building

Babraham Research Campus

Cambridge,  CB22 3AT

United Kingdom

Founded in 2009


44 1223 497 415

Key Executives for Bicycle Therapeutics Limited

Chief Executive Officer and Director
Scientific Founder
Scientific Founder
Age: 63
Chief Scientific Officer
Compensation as of Fiscal Year 2014.

Bicycle Therapeutics Limited Key Developments

ThromboGenics and Bicycle Therapeutics Seal Cooperation Agreement on Novel Ophthalmic Medicines

ThromboGenics announced that it has entered into a collaboration and licence agreement with Bicycle Therapeutics for the development and commercialisation of novel drugs that inhibit a particular target for the treatment of ophthalmic diseases, such as diabetic macular oedema/edema (DME). In particular, ThromboGenics intends to use the Bicycle Therapeutics bicyclic peptides for developing therapeutics that inhibit a target involved in vascular permeability. The companies will be collaborating on the preclinical development of these bicyclic peptide inhibitors; while ThromboGenics has an exclusive licence to take up the clinical development and commercialisation of identified drug candidates. In its turn, Bicycle will receive an upfront payment as well as development and regulatory milestone payments, and sales royalties, the details of which have not been disclosed. Significance: The selective inhibition of a target involved in vascular permeability is a new approach that could potentially help improve the DME treatment, a condition that affects around 30% of all patients who have suffered from diabetes for over 20 years and are at risk of developing the condition.

Bicycle Therapeutics Limited Presents at EBD Group's 7th Annual BIO-Europe Spring Conference 2013, Mar-11-2013

Bicycle Therapeutics Limited Presents at EBD Group's 7th Annual BIO-Europe Spring Conference 2013, Mar-11-2013 . Venue: Centre Covencions International Barcelona, Plaça de Willy Brandt, 11-14, 08019 Barcelona, Spain.

Similar Private Companies By Industry

Company Name Region
Biomed Reagents Limited Europe
Biogemma UK Ltd. Europe
Atazoa Limited Europe
Eco Group, LLC Europe
Burdica Biomedical Limited Europe

Recent Private Companies Transactions

Private Placement
October 14, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Bicycle Therapeutics Limited, please visit www.bicycletherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.